Andhira Vieira

Andhira Vieira

Auto-generated profile, based on publicly available information

Andhira Vieira

Université Côte d'Azur, CNRS, INSERM, iBV, France

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2013 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
MCMonica Courtney
Monica Courtney
EGElisabet Gjernes
Elisabet Gjernes
NDNoémie Druelle
Noémie Druelle
CRChristophe Ravaud
Christophe Ravaud
AVAndhira Vieira
Andhira Vieira
PCPatrick Collombat
Patrick Collombat
Recently, it was demonstrated that pancreatic new-born glucagon-producing cells can regenerate and convert into insulin-producing β-like cells through the ectopic expression of a single gene, Pax4. Here, combining conditional loss-of-function and lineage tracing approaches, we show that the selective inhibition of the Arx gene in α-cells is sufficient to promote the conversion of adult α-cells into β-like cells at any age. Interestingly, this conversion induces the continuous mobilization of duct-lining precursor cells to adopt an endocrine cell fate, the glucagon+ cells thereby generated being subsequently converted into β-like cells upon Arx inhibition. Of interest, through the generation and analysis of Arx and Pax4 conditional double-mutants, we provide evidence that Pax4 is dispensable for these regeneration processes, indicating that Arx represents the main trigger of α-cell-mediated β-like cell neogenesis. Importantly, the loss of Arx in α-cells is sufficient to regenerate a functional β-cell mass and thereby reverse diabetes following toxin-induced β-cell depletion. Our data therefore suggest that strategies aiming at inhibiting the expression of Arx, or its molecular targets/co-factors, may pave new avenues for the treatment of diabetes. Type 1 diabetes is a condition that results from the loss of insulin-producing β-cells. Despite current therapies, diabetic patients are prone to vascular complications. Using the mouse as a model, we previously found that pancreatic glucagon-expressing cells can be regenerated and converted into β-like cells by the forced expression of a single gene, Pax4. Here, we generated transgenic mice allowing both the permanent labeling of α-cells and the inactivation of Arx solely in this cell subtype. Our results indicate that, upon Arx inactivation, α-cells can be continuously regenerated from duct-lining precursors and converted into β-like cells. Importantly, the additional loss of Pax4 does not impact these processes, suggesting that Arx is the main trigger of α-cell-mediated β-like cell neogenesis. Most interestingly, upon chemical induction of diabetes/β-cell loss, while control animals die or remain severely hyperglycemic, a normalization of the glycemia, a clear regeneration of the β-like cell mass, and an extended lifespan are noted in animals with the conditional inactivation of Arx. Our data therefore suggest that strategies aiming at inhibiting the expression of Arx, or its molecular targets/co-factors, may pave new avenues for the treatment of diabetes.

1 July 2013 in Developmental Cell
Verified
Journal Article
Closed access
KAKeith Al-Hasani
Keith Al-Hasani
APAnja Pfeifer
Anja Pfeifer
MCMonica Courtney
Monica Courtney
NBNouha Ben-Othman
Nouha Ben-Othman
EGElisabet Gjernes
Elisabet Gjernes
PCPatrick Collombat
Patrick Collombat

1 August 2015 in Seminars in Cell & Developmental Biology
Verified
Journal Article
Closed access
TNTiziana Napolitano
Tiziana Napolitano
FAFabio Avolio
Fabio Avolio
MCMonica Courtney
Monica Courtney
AVAndhira Vieira
Andhira Vieira
NDNoémie Druelle
Noémie Druelle
PCPatrick Collombat
Patrick Collombat

15 October 2013 in Cell Cycle
Verified
Journal Article
Open access
APAnja Pfeifer
Anja Pfeifer
MCMonica Courtney
Monica Courtney
NBNouha Ben-Othman
Nouha Ben-Othman
KAKeith Al-Hasani
Keith Al-Hasani
EGElisabet Gjernes
Elisabet Gjernes
PCPatrick Collombat
Patrick Collombat
The pancreas is an organ that can be subdivided into 2 functionally distinct compartments: (1) the exocrine tissue, composed of acinar and ductal cells, which are, respectively, implicated in the s...

1 July 2013 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
NBNouha Ben-Othman
Nouha Ben-Othman
MCMonica Courtney
Monica Courtney
AVAndhira Vieira
Andhira Vieira
APAnja Pfeifer
Anja Pfeifer
NDNoémie Druelle
Noémie Druelle
PCPatrick Collombat
Patrick Collombat

1 January 2012 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
ABAdrien Botta
Adrien Botta
FDFrédéric Delteil
Frédéric Delteil
AMAmel Mettouchi
Amel Mettouchi
AVAndhira Vieira
Andhira Vieira
SESoline Estrach
Soline Estrach
GLGagnoux-Palacios Laurent
Gagnoux-Palacios Laurent
In culture, cell confluence generates signals that commit actively growing keratinocytes to exit the cell cycle and differentiate to form a stratified epithelium. Using a comparative proteomic approach, we studied this ‘confluence switch’ and identified a new pathway triggered by cell confluence that regulates basement membrane (BM) protein composition by suppressing the uPA/uPAR/plasmin pathway. Indeed, confluence triggers adherens junction maturation and enhances TGF-β/activin A activity, resulting in increased deposition of PAI-1 and perlecan in the BM. Extracellular matrix (ECM)-accumulated PAI-1 suppresses uPA/uPAR/plasmin pathway and further enhances perlecan deposition by inhibiting its plasmin-dependent proteolysis. We show that perlecan deposition in the ECM strengthens cell adhesion, inhibits keratinocyte motility and promotes additional accumulation of PAI-1 in the ECM at confluence. In agreement, during wound-healing, perlecan concentrates at the wound-margin, where BM matures to stabilize keratinocyte adhesion. Our results demonstrate that confluence dependent-signaling orchestrates not only growth-inhibition and differentiation but also controls ECM-proteolysis and BM formation. These data suggest that uncontrolled integration of confluence-dependent signaling, may favor skin disorders, including tumorigenesis, not only by promoting cell hyperproliferation but also by altering protease activity and deposition of ECM components.